drugset / Trial / NCT06501534
A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects
RandomizedParallel-groupOpen-labelTreatment
Summary
IBI128 (Tigulixostat) is a novel non-purine selective inhibitor of xanthine oxidase (XO). The XO inhibitors lower uric acid concentrations in serum by inhibiting the production of uric acid. This ia a randomized, open label, multicenter, parallel-group, positive-controlled, dose finding, and Phase II study to assess efficacy and safety of IBI128 in chinese gout subjects.
Timeline
- Start
- 2024-07-10
- Primary completion
- 2024-12-13
- Completion
- 2025-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Febuxostat | Small molecule | 40 mg | Oral |
| Subject | IBI128 | Unknown | 50 mg | Oral |
| Subject | IBI128 | Unknown | 100 mg | Oral |
| Subject | IBI128 | Unknown | 200 mg | Oral |